PHGE BiomX Inc

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates.

To participate in the conference call, please dial 1-877-407-0724 (U.S.) or (International). The live and archived  will be available in the Investors section of the Company’s website at .

About BiomX

BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit , the content of which does not form a part of this press release.

BiomX, Inc.

Ben Cohen

Head Corporate Communications



EN
08/05/2025

Underlying

PHGEBiomX Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BiomX Inc

 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX to Host First Quarter 2025 Financial Results Conference Call and...

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025 NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, pleas...

11h / 39m 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Discl...

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's indepe...

April 1, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating...

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reduci...

March 31, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and ...

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates In February 2025, BiomX announced a series of financings with total gross proceeds of approximately $12 million to support completion of Phase 2b study of BX004; topline results anticipated in Q1 2026Topline Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) expected by end of March 2025Initiated exploration and analysis of real-world evidence in people with Cystic Fibrosis (CF) on the relationship between Pseudomonas aeruginosa reduction and clinical outcomes, ahead of ex...

March 25, 2025 1 EN
 PRESS RELEASE
Free
PHGE BIOMX INC

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on...

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company’s websit...

March 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch